Freenome, Inc.

PCSC, a special purpose acquisition company targeting the healthcare and life sciences sector, filed an 8-K current report with the Securities and Exchange Commission on July 24, 2026, disclosing a material event involving Freenome, Inc., a clinical-stage biotechnology company focused on early cancer detection through blood-based multi-analyte diagnostics. Freenome has developed a liquid biopsy platform that applies machine learning to genomic and proteomic signals with the goal of identifying cancer at early, more treatable stages. The filing marks a notable development in the SPAC's trajectory within the oncology diagnostics space, an area that has drawn sustained blank-check vehicle interest. Sign up at SpacDesk for full data on PCSC, including sponsor details, deal terms, and filing history.